Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Free Cash Flow (2016 - 2025)

Rein Therapeutics filings provide 10 years of Free Cash Flow readings, the most recent being -$3.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow rose 33.08% year-over-year to -$3.2 million, compared with a TTM value of -$19.4 million through Dec 2025, up 13.14%, and an annual FY2025 reading of -$19.4 million, up 13.14% over the prior year.
  • Free Cash Flow hit -$3.2 million in Q4 2025 for Rein Therapeutics, up from -$3.5 million in the prior quarter.
  • The five-year high for Free Cash Flow was -$1.6 million in Q3 2023, with the low at -$10.4 million in Q4 2023.
  • Median Free Cash Flow over the past 5 years was -$5.5 million (2022), compared with a mean of -$5.5 million.
  • The sharpest move saw Free Cash Flow skyrocketed 76.47% in 2023, then plummeted 169.22% in 2024.
  • Year by year, Free Cash Flow stood at -$6.3 million in 2021, then rose by 29.51% to -$4.4 million in 2022, then plummeted by 135.68% to -$10.4 million in 2023, then soared by 53.69% to -$4.8 million in 2024, then soared by 33.08% to -$3.2 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$3.2 million, -$3.5 million, and -$6.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.